Drug
SNS-595
SNS-595 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
NCT00298896
completedphase_1
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
NCT00091585
completedphase_1
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
NCT00094159
Clinical Trials (3)
Showing 3 of 3 trials
NCT00298896Phase 2
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
NCT00091585Phase 1
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
NCT00094159Phase 1
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3